Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent

Abstract

Thrombosis, the blockage of blood vessels with clots, can lead to acute myocardial infarction and ischemic stroke, both leading causes of death. Other than surgical interventions to remove or by pass the blockage, or the generation of collateral vessels to provide a new blood supply, the only treatment available is the administration ofthrombolytic agents to dissolve the blood clot. In this review, Desire Collen considers the properties and characteristics of staphylokinase that make it the thrombolytic agent of choice.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Collen, D. & Lijnen, H.R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78, 3114–3124 (1991).

    CAS  Google Scholar 

  2. Schlandt, R.C. (Chairman). Reperfusion in acute myocardial infarction. Circulation 90, 2091–2102 (1994).

    Article  Google Scholar 

  3. Collen, D. Fibrin-selective thrombolytic therapy for acute myocardial infarction. Circulation 93, 857–865 (1996).

    Article  CAS  Google Scholar 

  4. Collen, D. Trials comparing the available thrombolytic agents. Coron. Art. Dis. 3, 117–122 (1992).

    Google Scholar 

  5. Grünewald, M. & Seifried, E. Meta-analysis of all available published clinical trials (1958-1990) on thrombolytic therapy for AMI: relative efficacy of different ther-apeytic strategies. Fibrinolysis 8, 67–86 (1994).

    Article  Google Scholar 

  6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 329, 673–682 (1993).

  7. Collins, R., Peto, R., Baigent, C. & Sleight, P., pirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N. Engl. J. Med. 336, 847–860 (1997).

    Article  CAS  Google Scholar 

  8. Califf, R.M. et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation 94, 1233–1238 (1996).

    Article  CAS  Google Scholar 

  9. Califf, R.M. et al. Selection of thrombolytic therapy for individual patients: development of a clinical model. Am. Heart J. 133, 630–639 (1997).

    Article  CAS  Google Scholar 

  10. Lack, C.H. Staphylokinase: an activator of plasma protease. Nature 161, 559–560 (1948).

    Article  CAS  Google Scholar 

  11. Gerheim, E.B. Staphylococcal coagulation and fibrinolysis. Nature 162, 732 (1948).

    Article  CAS  Google Scholar 

  12. Christensen, L.R. Streptococcal fibrinolysis: a proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysin. J. Gen. Physiol. 28, 363–383 (1945).

    Article  CAS  Google Scholar 

  13. Lewis, J.H., Kerber, C.W. & Wilson, J.H. Effects of fibrinolytic agents and heparin on intravascular clot lysis. Am. J. Physiol. 207, 1044–1048 (1964).

    CAS  PubMed  Google Scholar 

  14. Kanae, K. Fibrinolysis by staphylokinase in vivo. Tokyo Jikeika Med. J. 100, 925–934 (1985).

    CAS  Google Scholar 

  15. Collen, D. et al. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. Eur. J. Biochem. 216, 307–314 (1993).

    Article  CAS  Google Scholar 

  16. Collen, D. & Lijnen, H.R., phylokinase, a fibrin-specific plasminogen activator with therapeutic potential ? Blood 84, 680–686 (1994).

    CAS  PubMed  Google Scholar 

  17. Sako, T. et al. Cloning and expression of the staphylokinase gene of Staphylococcus aureus in Escherichia coli. Mol. Cen. Genet. 190, 271–277 (1983).

    Article  CAS  Google Scholar 

  18. Behnke, D. & Gerlach, D. Cloning and expression in Escherichia coli, Bacillus subtilis, and Streptococcus sanguis of a gene for staphylokinase - a bacterial plasminogen activator. Mol. Gen. Genet. 210, 528–534 (1987).

    Article  CAS  Google Scholar 

  19. Collen, D., Silence, K., Demarsin, E., De Mol, M. & Lijnen, H.R. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 6, 203–213 (1992).

    Article  CAS  Google Scholar 

  20. Sako, T. & Tsuchida, N. Nucleotide sequence of the staphylokinase gene from Staphylococcus aureus. Nucleic Acids Res. 11, 7679–7693 (1983).

    Article  CAS  Google Scholar 

  21. Collen, D., Zhao, Z.A., Holvoet, P. & Marijnen, P. Primary structure and gene structure of staphylokinase. Fibrinolysis 6, 226–231 (1992).

    Article  CAS  Google Scholar 

  22. Rabijns, A., De Bondt, H.L. & De Ranter, C. Three-dimensional-structure of staphylokinase, a plasminogen activator with therapeutic potential. Nat. Struct. Biol. 4, 357–360 (1997).

    Article  CAS  Google Scholar 

  23. Schlott, B., Gührs, K.H., Hartmann, M., Röcker, A. & Collen, D. Staphylokinase requires NH2-terminal proteolysis for plasminogen activation, J. Biol. Chem. 272, 6067–6072 (1997).

    Article  CAS  Google Scholar 

  24. Collen, D. et al. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J. Biol. Chem. 268, 8284–8289 (1993).

    CAS  PubMed  Google Scholar 

  25. Sakharov, D.V., Lijnen, H.R. & Rijken, D.C. Interactions between staphylokinase, plasmin(ogen) and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J. Biol. Chem. 271, 27912–27918 (1996).

    Article  CAS  Google Scholar 

  26. Lijnen, H.R. et al. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J. Biol. Chem. 266, 11826–11832 (1991).

    CAS  PubMed  Google Scholar 

  27. Lijnen, H.R., Van Hoef, B., Vandenbossche, L. & Collen, D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 6, 214–225 (1992).

    Article  CAS  Google Scholar 

  28. Sabovic, M., Lijnen, H.R., Keber, D. & Collen, D. Effect of retraction on the lysis of human clots with fibrin-specific and non-fibrin specific plasminogen activators. Thromb. Haemost. 62, 1083–1087 (1989).

    Article  CAS  Google Scholar 

  29. Sakai, M., Watanuki, M. & Matsuo, O. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of α2-plasmin inhibitor. Biochem. Biophys. Res. Commun. 162, 830–837 (1989).

    Article  CAS  Google Scholar 

  30. Lijnen, H.R., Van Hoef, B., Matsuo, O. & Collen, D. On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochim. Biophys. Ada 1118, 144–148 (1992).

    Article  CAS  Google Scholar 

  31. Silence, K., Collen, D. & Lijnen, H.R. Regulation by α2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma. Blood 82, 1175–1183 (1993).

    CAS  PubMed  Google Scholar 

  32. Lijnen, H.R., De Cock, F., Matsuo, O. & Collen, D. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis 6, 33–37 (1992).

    Article  CAS  Google Scholar 

  33. Collen, D. et al. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 6, 232–242 (1992).

    Article  CAS  Google Scholar 

  34. Collen, D., De Cock, F. & Stassen, J.M. Comparative immunogenicity and thrombolytic properties towards arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 87, 996–1006 (1993).

    Article  CAS  Google Scholar 

  35. Collen, D. & Van de Werf, F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 87, 1850–1853 (1993).

    Article  CAS  Google Scholar 

  36. Schlott, B. et al. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology 12, 185–189 (1994).

    CAS  PubMed  Google Scholar 

  37. Vanderschueren, S. et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation 92, 2044–2049 (1995).

    Article  CAS  Google Scholar 

  38. Vanderschueren, S., Collen, D. & Van de Werf, F. A pilot study on bolus administration of recombinant staphylokinase for coronary artery thrombolysis. Thromb. Haemost 76, 541–544 (1996).

    Article  CAS  Google Scholar 

  39. Vanderschueren, S. et al. A pilot randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am. Heart J. 134, 213–219 (1997).

    Article  CAS  Google Scholar 

  40. Vanderschueren, S. et al. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 92, 2050–2057, (1995).

    Article  CAS  Google Scholar 

  41. Declerck, P.J., Vanderschueren, S., Billiet, J., Moreau, H. & Collen, D. Prevalence and induction of circulating antibodies against recombinant staphylokinase. Thromb. Haemost. 71, 129–133 (1994).

    Article  CAS  Google Scholar 

  42. Collen, D. et al. Recombinant staphylokinase variants with altered immunoreactiv-ity. I. Construction and characterization. Circulation 94, 197–206, (1996).

    Article  CAS  Google Scholar 

  43. Collen, D., Moreau, H., Stockx, L. & Vanderschueren, S. Recombinant staphylokinase variants with altered immunoreactivity II. Thrombolytic properties and antibody induction. Circulation 94, 207–216 (1996).

    Article  CAS  Google Scholar 

  44. Vanderschueren, S., Stassen, J.M. & Collen, D. Comparative antigenicity of recombinant wild-type staphylokinase (SakSTAR) and a selected mutant (SakSTAR M38) in a baboon thrombolysis model. J. Cardiovasc. Pharmacol. 27, 809–815 (1996).

    Article  CAS  Google Scholar 

  45. Collen, D. et al. Recombinant staphylokinase variants with altered immunoreactivity III. Species variability of antibody binding patterns. Circulation 95, 455–462 (1997).

    Article  CAS  Google Scholar 

  46. Collen, D., Stockx, L., Lacroix, H., Suy, R. & Vanderschueren, S. Recombinant staphylokinase variants with altered immunoreactivity IV. Identification of variants with reduced antibody induction but intact potency. Circulation 95, 463–472 (1997).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collen, D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 4, 279–284 (1998). https://doi.org/10.1038/nm0398-279

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0398-279

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing